# Amgen Inc. (AMGN) — Q1-2026 Earnings Results

**Report date:** 2026-04-30 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/AMGN/earnings/Q1-2026

## Analyst Estimates

- **Consensus EPS:** $4.76 (range $4.17–$5.24)
- **Consensus revenue:** $8582.26

## Post-Earnings Brief

### Headline

Amgen Beats on EPS, Stock Up 2.43%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $5.15 | $4.76 | +8.88% |
| Revenue | N/A | $8.6B | N/A |

### Management Commentary

**Tone:** Unknown

No transcript is on record, and the analysis is based on numerical results only.

### Guidance Changes

No guidance data is available.

### What It Means

Amgen's earnings report showed a strong performance on EPS, exceeding expectations by nearly 9%. This positive surprise contributed to a 2.43% increase in the stock price. However, the lack of revenue data and management commentary leaves some uncertainty about the overall business outlook.

## Pre-Earnings Brief

### Company Snapshot

Amgen Inc. is a leading biotechnology company focused on developing innovative therapies for serious illnesses. Operating in the Health Care sector, Amgen is known for its advancements in biologic medicines, which are crucial for treating conditions like cancer and autoimmune diseases.

### Key Metrics to Watch

- **Earnings Per Share (EPS)** (consensus $4.76) — EPS is a key indicator of profitability and will show how well Amgen is managing its costs and generating income.
- **Revenue** (consensus $8.6B) — Revenue figures provide insight into the overall sales performance and market demand for Amgen's products.

### Last Quarter Recap

In Q4-2025, Amgen reported an EPS of $5.29, exceeding expectations by 11.18%. Despite the positive earnings surprise, the stock experienced a slight decline the following day.

### Wall Street Expectations

Analysts are generally optimistic about Amgen's upcoming earnings, expecting solid EPS and revenue figures. The company has consistently beaten EPS estimates in recent quarters, which adds to the positive sentiment.

**Bull case:** If Amgen continues its trend of beating EPS estimates, it could signal strong operational efficiency and product demand, potentially leading to a stock price increase.

**Bear case:** Conversely, if Amgen fails to meet expectations or provides weak guidance, it could raise concerns about future growth, leading to a negative reaction in the stock price.

### Options Signal

Implied move: **4.3%**
Historical avg move: 0.8%
Pricing: rich — Options are pricing a 4.3% move, while the stock has averaged only 0.8% over the last 8 quarters — setup is rich.

The options market is pricing in a significant move around the earnings announcement, indicating that traders expect volatility.

### Earnings Track Record

| Quarter | EPS Surprise | 1-Day Reaction |
|---|---|---|
| Q4-2025 | +11.18% | -1.77% |
| Q3-2025 | +12.75% | +0.13% |
| Q2-2025 | +15.61% | -0.62% |
| Q1-2025 | +17.85% | -2.45% |
| Q4-2024 | +5.59% | +0.05% |

### Pivotal Questions

1. **Will Amgen's EPS exceed the consensus estimate of $4.76?**
   - Why it matters: A strong EPS performance could reinforce investor confidence and support a positive stock reaction.
2. **What guidance will Amgen provide for future revenue growth?**
   - Why it matters: Insights into future revenue expectations will be critical for assessing the company's growth trajectory and market positioning.

### Thesis Break Levels

- **Bull trigger:** An EPS of $5.00 or higher would confirm the bull case, indicating strong operational performance.
- **Bear trigger:** An EPS below $4.50 would confirm the bear case, raising concerns about profitability.

The market is debating whether Amgen can maintain its strong earnings performance amid competitive pressures and market conditions.

### Scenario Playbook

- **Beat & raise:** If Amgen beats expectations, history suggests a potential stock increase of around 0.6%, confirming strong operational performance.
- **In-line / cautious:** If results are in line with expectations but management is cautious, the stock may react neutrally as investors reassess future growth.
- **Miss:** If Amgen misses expectations, history suggests a potential decline of around 0.4%, raising concerns about future profitability.

### What the Street is Missing

The Street may be underestimating Amgen's ability to sustain its earnings momentum, given the recent strong performance and potential for new product launches.

**Supporting points:**

- Amgen has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.
- The options market is pricing in a larger move than historical averages, suggesting heightened expectations.
- Insider trading patterns show mixed signals, which could indicate uncertainty about future performance.

**Risk to consensus:** If EPS comes in below $4.50, it could undermine the bullish sentiment and lead to a reevaluation of growth expectations.

### Setup Pattern Insight

Pattern: **Prior-quarter beat + options rich in Health Care** (sample size n=30, fade rate 7 of 23 (30%))

This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).

### What to Listen For

- Any commentary on new product launches and their expected impact on revenue.
- Insights into cost management strategies and their effect on profitability.
- Updates on competitive pressures in the biotechnology sector.
- Any changes in guidance for future quarters, especially regarding revenue growth.
- Management's view on market conditions and their potential impact on Amgen's performance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/AMGN/earnings/Q1-2026_